Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 RedHill Licenses RHB-102 to Hyloris | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

RedHill Licenses RHB-102 to Hyloris

If approved, RHB-102 will provide the opportunity to deliver 24-hour relief from nausea and vomiting in a single pill.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

RedHill Biopharma Ltd., a specialty biopharmaceutical company, has entered into an exclusive worldwide development and commercialization licensing agreement, excluding North America, with Hyloris Pharmaceuticals SA for RedHill’s RHB-102 (Bekinda).

Under the terms of the Agreement, Hyloris will pay RedHill an upfront payment, in addition to up to $60 million in potential milestone payments, contingent upon achieving specified commercial targets, plus up to mid-20s percent royalties on revenues, subject to certain cost recoupments, with minimum annual payments to RedHill, in return for exclusive rights to RHB-102 across all indications and territories outside the United States, Canada and Mexico. RedHill intends to continue development of RHB-102 for FDA approval in the U.S., if granted. Hyloris will be responsible for all development, regulatory and commercialization activities related to RHB-102 in its territories.

RHB-102 is a once-daily, proprietary, bimodal extended-release oral tablet formulation of ondansetron, a 5-HT3 antagonist in advanced development for oncology support, acute gastroenteritis and gastritis, and diarrhea-predominant irritable bowel syndrome (IBS-D) at two dose strengths: 12mg and 24mg.

“Ondansetron ER will be a valuable addition to supportive care in oncology and post-surgical settings, where sustained relief from nausea is essential,” said Thomas Jacobsen, Co-Chief Executive Officer of Hyloris. “We are committed to delivering innovative solutions that enhance patient comfort and streamline therapy, especially in areas where reducing treatment burden can make a meaningful impact. We look forward to collaborating with RedHill to bring this product to patients.”

“Our new partners at Hyloris share our vision of RHB-102’s significant potential, and we look forward to working with them to bring RHB-102 to patients worldwide,” said Dror Ben-Asher, CEO of RedHill. “This agreement follows the recent initiation of the Bayer-funded Phase 2 study of opaganib and darolutamide in advanced prostate cancer and is further demonstration of the potential of RedHill’s R&D pipeline. If approved, RHB-102 will provide the opportunity to deliver 24-hour relief from nausea and vomiting in a single pill for outpatient use by cancer patients undergoing chemotherapy or radiotherapy, and those with acute gastroenteritis, gastritis or IBS-D.”

Recent positive advice from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) provided a clear pathway for a UK Marketing Authorization Application (MAA) for RHB-102 (24 mg) for oncology support (CINV and RINV) in the UK, and potentially in other countries, subject to completion of certain manufacturing activities. If approved, RHB-102 could be the first oral 24-hour extended-release ondansetron antiemetic drug for the treatment of chemotherapy/radiotherapy-induced nausea and vomiting (CINV/RINV).

RedHill also completed successful U.S. Phase 3 and 2 studies for acute gastroenteritis & gastritis (24 mg) and IBS-D (12 mg), meeting primary endpoints. RHB-102 may also be used for post-operative nausea and vomiting (PONV).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics